ArticleJournal of personalized medicine2022

The Cost-Effectiveness Analysis of Transplant-Ineligible Myeloma Patients with Bortezomib plus Thalidomide plus Dexamethasone (VTD) or Bortezomib plus Melphalan plus Prednisolone (VMP) Treatment in Southern Taiwan.

Jeng-Shiun Du et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.